Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
Sean Wharton, Carel Wynand le Roux, Elena Startseva, Isabel M. Kloer, Ahmad Alhussein, Samina Ajaz Hussain, Anna Unseld, Biykem Bozkurt, Jamy D. Ard, Harold Edward Bays, Paweł Bogdański, Jawad H. Butt, Elif Ilhan Ekinci, Ania M. Jastreboff, Linong Ji, Morten Schou, Francisco José Tinahones, Alexander D. Kokkinos, Béla Péter Merkely, Wataru Ogawa, Sue D. Pedersen, Kirsi Hannele Pietiläinen, Dean Quinn, Naveed A. Sattar, Jochen Seufert, Kaj Stenlöf, André P. van Beek, Roman Vangoitsenhoven, Martina Brueckmann, Ramy Younes, Lee M. Kaplan
Revista con revisión por paresUso en el mundo real
En palabras de los autores
Esta revista no permite republicar el resumen completo. Estas son las dos oraciones que eligió Pipette, citadas textualmente. El resto está en el sitio de la editorial.
Resultado principal
ConclusionsIn adults with obesity and type 2 diabetes, survodutide at a weekly dose of 3.6 mg or 6.0 mg resulted in significantly greater weight reduction than placebo.
Here, we identified a neuroendocrine pathway through which hypertension accelerates OA pathogenesis in joints predisposed by mechanical injury or aging.
Su-Jin Kim, Hyoeun Kim, Ki‐Ho Chung y 15 más — Science
Among individuals after MI, moment-to-moment negative affect during one week of monitoring in daily life is a powerful predictor of subsequent cardiovascular events.
Together, these findings support NMR metabolomics as a common approach to risk stratification across the cardiovascular-kidney-metabolic disease continuum and illustrate how NMR-enhanced risk estimates could be integrated with longitudinal clinical information.
J. Chacon-Barahona, C. Iribarren, J. S. Rana y 6 más — medRxiv
The results from this trial indicate that mechanisms of kidney protection by semaglutide may include reduced vascular resistance, prevention of fibrosis and improved underlying molecular programs promoting endothelial cell health.
Katherine R. Tuttle, Petter Bjornstad, Cathy Smith y 12 más — Nature Medicine
Revista con revisión por paresUso en el mundo real
Conclusion: Diabetes testing coverage in Kenya remains low, with more than half of diabetes cases remaining undiagnosed and substantial losses occurring across the diabetes care cascade.
C. Akoth, C. V. Thomas, J. O. Oguta y 2 más — medRxiv